MicroPort Received CE Approval for FireMagic™, EasyFinder™, EasyLoop™ and FireMagic™ 3D
Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that the 4 products which are FireMagic™ radiofrequency ablation catheter, EasyFinder™ fixed or adjustable curved mapping catheter, EasyLoop™ circumferential pulmonary vein mapping catheter and FireMagic™ 3D saline infusion radiofrequency ablation catheter received CE certificate on Nov 20th 2013.
FireMagic™ radiofrequency ablation catheter is used in the cardiac electrophysiology diagnostic procedure and radiofrequency ablation. EasyFinder™ fixed or adjustable curved mapping catheter is mainly used in detailed mapping of electrical cardiac arrhythmia examination which detects different electrophysiological signal. EasyLoop™ circumferential pulmonary vein mapping catheter is used to detect and extract different signal in pulmonary vein isolation, which is indispensable to the ablation procedure for the treatment of atrial fibrillation.
FireMagic™ 3D saline infusion radiofrequency ablation catheter is mainly used in ablation procedure by providing precise location of the catheter tip in the body and collecting cardiac ECG signal to help physician to effectively maneuver the ablation catheter in the body during the procedure. Currently, the procedure of catheter ablation is gaining wide acceptance in the treatment of atrial fibrillation. The use of FireMagic™ 3D combined with Columbus™ 3D cardiac mapping system provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias. In addition, Columbus™ with FireMagic™ 3D is the only domestically developed 3D mapping system with the CE certificate.
According to the report from MILLENNIUM RESEARCH GROUP at EUROPEAN MARKETS FOR ELECTROPHYSIOLOGY MAPPING AND ABLATION DEVICES 2012, it is expected that the market for diagnostic catheter and ablation catheter will reach $310 million in 2013. By the end of 2011, the patient population with atrial fibrillation reached 3.3 million in Europe. The procedure volume for atrial fibrillation treatment is expected to reach 36,000 cases in 2013 representing an annual growth rate of 15.1%. The CE approval with the products provides foundation in entering international market for MicroPort Group.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.